Strand Therapeutics
NEWS
40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-front and up to $1.225 billion in total consideration.
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
Strand Therapeutics’ lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing the immunomodulatory protein IL-12.
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
IN THE PRESS
JOBS